CO-TRIMOXAZOLE
sravssmiling1521@gmail.com
Dr. KONERU NAGA SRAVANTHI,
ASSOCIATE PROFESSOR,
MALLA REDDY COLLEGE OF PHARMACY,
HYDERABAD.
• cotrimoxazole is fixed dose combination of
Trimethoprim and Sulfamethoxazole.
Mechanism of action
• Bactericidal
 Sequential block of folate metabolism
• Trimethoprim inhibits bacterial tetrahydrofolate
reductase (THFRase)
• Sulfamethoxazole inhibits bacterial dihydrofolate
reductase (DHFRase)
It is also active on S.typhi, serratia, Enterobacter,
Klebisella. Etc.,
Trimethoprim Sulfamethoxazole
Spectrum Bacteristatic Bacteristatic
Mechanism of action THFRase inhibition DHFRase inhibition
t1/2 Nearly 10 hr Nearly 10 hr
Dose ratio in cotrimoxazole 5 1
Plasma concetration ratio
in blood
20 1
Absorption Rapid Slow
BBB crossing Adequate poor
Plasma protein binding 40% 65%
Adverse Effects:
• All ADRS of Sulfonamides
• In folate deficiency: Megaloblastic Anaemia
• Blood Dyscrasias
• In renal disease: uremia develops
• In elderly:Bone marrow toxicity
• In pregnancy: Avoid the drug usage due to
teratogenic ris
 Uses:
• Urinary Infections
• Respiratory Tract Infections
• Typhoid
• Bacterial Diarrhoeas and dysentery
• Chancroid
References
K. D. Tripathi, “Essentials of Medical
Pharmacology,” 7th Edition, Jaypee Brothers
Medical Publishers (P) LTD, New Delhi, 2003;
706-707.
Further reading:
KDT - Essentials of Medical Pharmacology -7th
Edition-.pdf
https://dvmbooks.weebly.com/uploads/2/2/3
/6/22365786/2._goodman_and_gilman.pdf

Cotrimoxazole

  • 1.
    CO-TRIMOXAZOLE sravssmiling1521@gmail.com Dr. KONERU NAGASRAVANTHI, ASSOCIATE PROFESSOR, MALLA REDDY COLLEGE OF PHARMACY, HYDERABAD.
  • 2.
    • cotrimoxazole isfixed dose combination of Trimethoprim and Sulfamethoxazole. Mechanism of action • Bactericidal  Sequential block of folate metabolism • Trimethoprim inhibits bacterial tetrahydrofolate reductase (THFRase) • Sulfamethoxazole inhibits bacterial dihydrofolate reductase (DHFRase) It is also active on S.typhi, serratia, Enterobacter, Klebisella. Etc.,
  • 3.
    Trimethoprim Sulfamethoxazole Spectrum BacteristaticBacteristatic Mechanism of action THFRase inhibition DHFRase inhibition t1/2 Nearly 10 hr Nearly 10 hr Dose ratio in cotrimoxazole 5 1 Plasma concetration ratio in blood 20 1 Absorption Rapid Slow BBB crossing Adequate poor Plasma protein binding 40% 65%
  • 4.
    Adverse Effects: • AllADRS of Sulfonamides • In folate deficiency: Megaloblastic Anaemia • Blood Dyscrasias • In renal disease: uremia develops • In elderly:Bone marrow toxicity • In pregnancy: Avoid the drug usage due to teratogenic ris
  • 5.
     Uses: • UrinaryInfections • Respiratory Tract Infections • Typhoid • Bacterial Diarrhoeas and dysentery • Chancroid References K. D. Tripathi, “Essentials of Medical Pharmacology,” 7th Edition, Jaypee Brothers Medical Publishers (P) LTD, New Delhi, 2003; 706-707.
  • 6.
    Further reading: KDT -Essentials of Medical Pharmacology -7th Edition-.pdf https://dvmbooks.weebly.com/uploads/2/2/3 /6/22365786/2._goodman_and_gilman.pdf